Market Research Reports, Inc. United Kingdom- Meningococcal Vaccine Market Analysis- 2022 announces the addition of “PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022” report that covers key pointers on drug market forecasts, opportunities and challenges, key events and analysis of key events.


Lewes, DE -- (SBWIRE) -- 07/18/2013 -- United Kingdom’s Drug forecast foresees a spectacular growth during 2011-2022. The launch of Serotype B vaccine has brought the critical unmet need in the treatment of Meningococcal disease to a better aid. As the acute infection’s rapid onset and severity of symptoms’ diagnosis is highly difficult, vaccines play a vital role in fighting of the disease caused by the gram-negative bacterium Neisseria meningitidis The tetravalent conjugate vaccines such as Sanofi’s Menactra and Novartis’ Menveo, accounted for major sales and growth of Meningococcal vaccines will be driven by Serotype B vaccines until the launch of Serotype B vaccines.

Patient share for 3 MenC conjugate vaccines will shift due to changes made to the UK MenC schedule (DOH, 2013b). Menjugate and NeisVac-C are expected to be combination of prescription for patients after elimination of single primary dose of Meningitec.

Spanning over 129 pages, 37 tables and 4 figures, “PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022” report addresses important factors such as Overview of Meningococcal Vaccines, safety and efficacy profiles as well as a SWOT analysis of companies in United Kindom and Sales forecast for the top drugs in the UK from 2012-2022.

Browse More Pharma and Healthcare Market Research Reports

About Market Research Reports, Inc.
Market Research Reports, Inc. ( is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.